L1CAM Further Stratifies Endometrial Carcinoma Patients with No Specific Molecular Risk Profile

Overview

Journal Br J Cancer

Specialty Oncology

Date 2018 Jul 28

PMID 30050154

Citations 52

Authors

Felix Kf Kommoss

Anthony N Karnezis

Friedrich Kommoss

Aline Talhouk

Florin-Andrei Taran

Annette Staebler

C Blake Gilks

David G Huntsman

Bernhard Kramer

Sara Y Brucker

Jessica N McAlpine

Stefan Kommoss

Affiliations

Soon will be listed here.

Abstract

Background: The newly developed Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE) has consistently been shown to be prognostically significant in endometrial carcinomas (EC). Recently, we and others have demonstrated L1 cell-adhesion molecule (L1CAM) to be a significant indicator of high-risk disease in EC. In the current study, it was our aim to determine the prognostic significance of aberrant L1CAM expression in ProMisE subgroups in a large, single centre, population-based EC cohort.

Methods: ProMisE (POLE; MMR-D; p53 wt/NSMP; p53 abn) classification results from a cohort of 452 EC were available for analysis. L1CAM expression was studied by immunohistochemistry on whole slides. Correlations between clinicopathological data and survival were calculated.

Results: Expression of L1CAM was most frequent in p53 abnormal tumours (80%). L1CAM status was predictive of worse outcome among tumours with no specific molecular profile (p53 wt/NSMP) (p < 0.0001). Among p53 wt/NSMP EC, L1CAM remained a significant prognosticator for disease-specific survival after multivariate analysis (p = 0.035).

Conclusion: L1CAM status was able to significantly stratify risk among tumours of the large p53 wt/NSMP ProMisE subgroup of EC. Furthermore, our study confirms a highly significant correlation between mutation-type p53 immunostaining and abnormal L1CAM expression in EC.

Citing Articles

The impact of integrated genomic analysis on molecular classifications and prognostic risk stratification in endometrial cancer: a Chinese experience.

Zheng Q, Shao D, Shu J, Zhang Q, Huang M, Wang D Front Oncol. 2025; 15:1541562.

PMID: 39980551 PMC: 11839450. DOI: 10.3389/fonc.2025.1541562.

Mismatch repair, p53, and L1 cell adhesion molecule status influence the response to chemotherapy in advanced and recurrent endometrial cancer.

Kim J, Ahn B, Lee Y, Nam E, Kim S, Kim S BMC Cancer. 2024; 24(1):1586.

PMID: 39734232 PMC: 11684106. DOI: 10.1186/s12885-024-13294-3.

Adjuvant Therapy for Endometrial Cancer in the Era of Molecular Classification.

Gupta S, Gupta R, Motwani V, Kalwaniya D J Midlife Health. 2024; 15(3):142-152.

PMID: 39610963 PMC: 11601929. DOI: 10.4103/jmh.jmh_88_24.

Role of Pyroptosis in Endometrial Cancer and Its Therapeutic Regulation.

Al Mamun A, Geng P, Wang S, Shao C J Inflamm Res. 2024; 17:7037-7056.

PMID: 39377044 PMC: 11457779. DOI: 10.2147/JIR.S486878.

Low-Risk and High-Risk NSMPs: A Prognostic Subclassification of No Specific Molecular Profile Subtype of Endometrial Carcinomas.

Marchetti M, Spagnol G, Vezzaro T, Bigardi S, Tommasi O, Facchetti E Cancers (Basel). 2024; 16(18).

PMID: 39335192 PMC: 11429616. DOI: 10.3390/cancers16183221.

References

Zorn A, Barish G, Williams B, Lavender P, Klymkowsky M, Varmus H . Regulation of Wnt signaling by Sox proteins: XSox17 alpha/beta and XSox3 physically interact with beta-catenin. Mol Cell. 1999; 4(4):487-98. DOI: 10.1016/s1097-2765(00)80200-2. View

Creutzberg C, van Putten W, Koper P, Lybeert M, Jobsen J, Warlam-Rodenhuis C . Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet. 2000; 355(9213):1404-11. DOI: 10.1016/s0140-6736(00)02139-5. View

Chafe S, Honore L, Pearcey R, Capstick V . An analysis of the impact of pathology review in gynecologic cancer. Int J Radiat Oncol Biol Phys. 2000; 48(5):1433-8. DOI: 10.1016/s0360-3016(00)00791-4. View

Fanning J . Long-term survival of intermediate risk endometrial cancer (stage IG3, IC, II) treated with full lymphadenectomy and brachytherapy without teletherapy. Gynecol Oncol. 2001; 82(2):371-4. DOI: 10.1006/gyno.2001.6276. View

J van t Veer L, Dai H, van de Vijver M, He Y, Hart A, Mao M . Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002; 415(6871):530-6. DOI: 10.1038/415530a. View

Fogel M, Gutwein P, Mechtersheimer S, Riedle S, Stoeck A, Smirnov A . L1 expression as a predictor of progression and survival in patients with uterine and ovarian carcinomas. Lancet. 2003; 362(9387):869-75. DOI: 10.1016/S0140-6736(03)14342-5. View

Gavert N, Conacci-Sorrell M, Gast D, Schneider A, Altevogt P, Brabletz T . L1, a novel target of beta-catenin signaling, transforms cells and is expressed at the invasive front of colon cancers. J Cell Biol. 2005; 168(4):633-42. PMC: 2171754. DOI: 10.1083/jcb.200408051. View

Li J, Mizukami Y, Zhang X, Jo W, Chung D . Oncogenic K-ras stimulates Wnt signaling in colon cancer through inhibition of GSK-3beta. Gastroenterology. 2005; 128(7):1907-18. DOI: 10.1053/j.gastro.2005.02.067. View

Paik S, Tang G, Shak S, Kim C, Baker J, Kim W . Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006; 24(23):3726-34. DOI: 10.1200/JCO.2005.04.7985. View

10.

Shtutman M, Levina E, Ohouo P, Baig M, Roninson I . Cell adhesion molecule L1 disrupts E-cadherin-containing adherens junctions and increases scattering and motility of MCF7 breast carcinoma cells. Cancer Res. 2006; 66(23):11370-80. DOI: 10.1158/0008-5472.CAN-06-2106. View

11.

Sinner D, Kordich J, Spence J, Opoka R, Rankin S, Lin S . Sox17 and Sox4 differentially regulate beta-catenin/T-cell factor activity and proliferation of colon carcinoma cells. Mol Cell Biol. 2007; 27(22):7802-15. PMC: 2169141. DOI: 10.1128/MCB.02179-06. View

12.

Mariani A, Dowdy S, Cliby W, Gostout B, Jones M, Wilson T . Prospective assessment of lymphatic dissemination in endometrial cancer: a paradigm shift in surgical staging. Gynecol Oncol. 2008; 109(1):11-8. PMC: 3667391. DOI: 10.1016/j.ygyno.2008.01.023. View

13.

Raveh S, Gavert N, Ben-Zeev A . L1 cell adhesion molecule (L1CAM) in invasive tumors. Cancer Lett. 2009; 282(2):137-45. DOI: 10.1016/j.canlet.2008.12.021. View

14.

Kalluri R, Weinberg R . The basics of epithelial-mesenchymal transition. J Clin Invest. 2009; 119(6):1420-8. PMC: 2689101. DOI: 10.1172/JCI39104. View

15.

Huszar M, Pfeifer M, Schirmer U, Kiefel H, Konecny G, Ben-Arie A . Up-regulation of L1CAM is linked to loss of hormone receptors and E-cadherin in aggressive subtypes of endometrial carcinomas. J Pathol. 2010; 220(5):551-61. DOI: 10.1002/path.2673. View

16.

Clarke B, Gilks C . Endometrial carcinoma: controversies in histopathological assessment of grade and tumour cell type. J Clin Pathol. 2010; 63(5):410-5. DOI: 10.1136/jcp.2009.071225. View

17.

Pfeifer M, Schirmer U, Geismann C, Schafer H, Sebens S, Altevogt P . L1CAM expression in endometrial carcinomas is regulated by usage of two different promoter regions. BMC Mol Biol. 2010; 11:64. PMC: 2939505. DOI: 10.1186/1471-2199-11-64. View

18.

Kiefel H, Pfeifer M, Bondong S, Hazin J, Altevogt P . Linking L1CAM-mediated signaling to NF-κB activation. Trends Mol Med. 2011; 17(4):178-87. DOI: 10.1016/j.molmed.2010.11.005. View

19.

Tischler V, Pfeifer M, Hausladen S, Schirmer U, Bonde A, Kristiansen G . L1CAM protein expression is associated with poor prognosis in non-small cell lung cancer. Mol Cancer. 2011; 10:127. PMC: 3198986. DOI: 10.1186/1476-4598-10-127. View

20.

Kiefel H, Bondong S, Hazin J, Ridinger J, Schirmer U, Riedle S . L1CAM: a major driver for tumor cell invasion and motility. Cell Adh Migr. 2012; 6(4):374-84. PMC: 3478260. DOI: 10.4161/cam.20832. View